| Literature DB >> 26612999 |
Maria A Morosanova1, Elena I Morosanova1.
Abstract
BACKGROUND: Salicylic acid and its derivatives are widely used drugs with potential toxicity. The main areas of salicylate derivatives determination are biological liquids and pharmaceuticals analysis.Entities:
Keywords: Acetylsalicylic acid; Human urine; Methylsalicylate; Pharmaceuticals analysis; Salicylamide; Salicylate; Silica-titania xerogels; Solid phase spectrophotometric determination; Synthetic serum
Year: 2015 PMID: 26612999 PMCID: PMC4660651 DOI: 10.1186/s13065-015-0142-z
Source DB: PubMed Journal: Chem Cent J ISSN: 1752-153X Impact factor: 4.215
Fig. 1Two possible complexes of salicylate with titanium(IV) on the titanium dioxide surfaces [22]. a The complex of salicylate with two titanium(IV) ions, b the complex of salicylate with one titanium(IV) ion
Fig. 2Absorption spectra of xerogels after reaction with salicylate derivatives (time of contact with salicylate derivatives is 15 min). a Chemical structures of salicylate derivatives and b absorption spectra of xerogels after reaction with salicylate derivatives 1 mM solutions. 1 sodium salicylate (pH 2.0), 2 salicylamide (pH 2.0), 3 methylsalicylate (pH 7.6)
Fig. 3The dependence of silica-titania xerogels absorbance on pH after the contact with salicylate derivatives. λ 410 nm, time of contact with salicylate derivatives is 15 min. 1 2 × 10−3 M sodium salicylate, 2 3 × 10−3 M salicylamide, 3 2.5 × 10−3 M methylsalicylate
Fig. 4The dependence of silica-titania xerogels absorbance on the time of contact with salicylate derivatives. λ 410 nm. 1 2 × 10−3 M sodium salicylate, pH 2.0, 2 3∙× 10−3 M salicylamide, pH 2.0, 3 2.5∙× 10−3 M methylsalicylate, pH 7.6
Characteristics of titanium(IV)—salicylate derivatives complexes in solid phase
| Salicylate derivative (L) | Ti:L ratio | lgKeq in solid phase |
|---|---|---|
| Salicylate | 1:0.5 | 2.0 |
| Salicylamide | 1:1 | 2.9 |
| Methylsalicylate | 1:1 | 3.4 |
Analytical characteristics of solid phase spectrophotometric determination of salicylate derivatives (λ 410 nm, time of contact is 15 min)
| Analytical range (mM) | Linear approximation | R | Limit of detection (mM) | |
|---|---|---|---|---|
| Sodium salicylate | 0.1–5 | A = 150·C | 0.9968 | 0.02 |
| Salicylamide | 0.5–10 | A = 86·C | 0.9983 | 0.03 |
| Methylsalicylate | 0.05–4.7 | A = 125·C | 0.9976 | 0.01 |
Recovery test of solid phase spectrophotometric determination of salicylate in biological liquids (n = 3, P = 0.95)
| Sample | Added (mM) | Found (mM) | RSD (%) | Recovery (%) |
|---|---|---|---|---|
| Synthetic seruma | 0.5 | 0.49 ± 0.10 | 10.9 | 98.0 |
| 1.0 | 0.97 ± 0.15 | 8.4 | 97.0 | |
| 1.5 | 1.42 ± 0.05 | 1.9 | 94.6 | |
| 2.0 | 2.09 ± 0.04 | 1.0 | 104.5 | |
| Urineb | 0 | 0.46 ± 0.07 | 8.3 | |
| 0.25 | 0.70 ± 0.09 | 7.2 | 96.0 | |
| 0.625 | 1.08 ± 0.07 | 3.5 | 99.2 |
aSynthetic serum composition is taken from [12]
bCollected 1 h after oral administration of 1000 mg of acetylsalicylic acid
Solid phase spectrophotometric determination of salicylate derivatives in real samples using the standard addition method (n = 3, P = 0.95)
| Sample | Analyte | Found (independent method) | Found (proposed method) |
|---|---|---|---|
| Deep Heat creama | Methylsalicylate | 128 mg/g (DC) | 123 ± 8 mg/g |
| Citramon tabletsb | Acetylsalicylic acid | 240 mg/tablet (DC) | 220 ± 10 mg/tablet |
| Acetylsalicylic acid tablets Tatkhim | Acetylsalicylic acid | 500 mg/tablet (DC) | 500 ± 20 mg/tablet |
| Acetylsalicylic acid tablets Medisorb | Acetylsalicylic acid | 500 mg/tablet (DC) | 510 ± 20 mg/tablet |
| Synthetic serumc, containing 1 mM salicylate | Salicylate | 1.03 ± 0.05 mM (TT) | 0.97 ± 0.15 mM |
| Urine sampled | Salicylate | 0.42 ± 0.01 mM (TT) | 0.46 ± 0.07 mM |
DC content declared by manufacturer
TT Trinder salicylate test
aContains additional active substances: menthol 59.1 mg/g, eucalyptus oil 19.7 mg/g, turpentine oil 14.7 mg/g
bContains additional active substances: paracetamol 180 mg/tablet, caffeine 30 mg/tablet
cSynthetic serum composition is taken from [12]
dCollected 1 h after oral administration of 1000 mg of acetylsalicylic acid
Determination of salicylate and methylsalicylate in mixed solutions (n = 3, P = 0.95)
| Composition | pH | Found, mM |
|---|---|---|
| Salicylate 2.5 mM | 2.0 | Salicylate 2.5 ± 0.2 |
| Methylsalicylate 1.9 mM | 7.6 | Methylsalicylate 1.97 ± 0.5 |
Recovery test of solid phase spectrophotometric determination of salicylate derivatives (n = 3, P = 0.95)
| Analyte | Sample | Added (mM) | Found (mM) | RSD (%) | Recovery (%) |
|---|---|---|---|---|---|
| Methylsalicylate | Deep heat creama | 0 | 1.01 ± 0.24 | 13.6 | |
| 0.91 | 1.85 ± 0.27 | 8.2 | 92.3 | ||
| 1.82 | 2.83 ± 0.24 | 4.9 | 100.0 | ||
| Acetylsalicylic acid | Acetylsalicylic acid tablets Medisorb | 0 | 0.57 ± 0.06 | 6.4 | |
| 0.55 | 1.07 ± 0.06 | 3.4 | 90.9 | ||
| 1.1 | 1.68 ± 0.06 | 2.2 | 100.9 | ||
| Acetylsalicylic acid tablets Tatkhim | 0 | 0.69 ± 0.09 | 7.6 | ||
| 0.55 | 1.20 ± 0.09 | 4.5 | 92.7 | ||
| 1.1 | 1.79 ± 0.09 | 2.9 | 100.0 | ||
| Citramon tabletsb | 0 | 0.49 ± 0.09 | 10.6 | ||
| 0.55 | 1.02 ± 0.15 | 7.7 | 96.4 | ||
| 1.1 | 1.58 ± 0.15 | 5.8 | 99.1 |
aContains additional active substances: menthol 59.1 mg/g, eucalyptus oil 19.7 mg/g, turpentine oil 14.7 mg/g
bContains additional active substances: paracetamol 180 mg/tablet, caffeine 30 mg/tablet